# METalmark (NCT05488314)

> A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer

No report yet. It can be ordered.

- Drugs tested: amivantamab plus capmatinib
- Indication: unresectable metastatic non-small cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05488314
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Janssen Research & Development, LLC
- Conditions: Carcinoma, Non-Small-Cell Lung
- Interventions: Capmatinib; Amivantamab
- Enrollment: 57
- Primary outcome: Phase 1: Number of Participants with Adverse events (AEs) by Severity
- Primary outcome: Phase 1: Number of Participants with Dose Limiting Toxicities (DLTs)
- Primary outcome: Phase 2: Objective Response Rate

## Indexed commentary on METalmark so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 1 YouTube video
- 1 podcast episode
- 1 post on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=metalmark-nct05488314